Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
NCT ID: NCT01745900
Last Updated: 2012-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
125 participants
OBSERVATIONAL
2012-12-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* collect subject data on a near-infrared spectroscopy-based glucose meter
* evaluate existing instrumentation, calibration algorithms and calibration maintenance techniques
* collect data on the physiological and environmental sources of interference and degradation of measurement accuracy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females with self reported diagnosis of Type I, Type II or Gestational Diabetes, or no self reported diagnosis of diabetes.
Exclusion Criteria
* Currently taking Lasix (self reported)
* Liver disease as evidenced by jaundice (self reported)
* Receiving dialysis or having known renal compromise (self reported)
* Skin damage at optical sampling site
* Scars, tattoos, rashes or other disruption/discoloration on the right index finger
* Recent (within past month) or current oral steroid therapy or topical steroids applied to the hands; inhaled steroid therapy (self reported)
* Current chemotherapy, or chemotherapy within the past 12 months (self reported)
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InLight Solutions
INDUSTRY
VeraLight, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amber Brassfield, RN
Role: PRINCIPAL_INVESTIGATOR
Accelovance
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Accelovance Inc.
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Amber Brassfield, RN
Role: CONTACT
Phone: 619-291-2845
Amber Brassfield, RN
Role: CONTACT
Phone: 619-366-1129
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VL-240
Identifier Type: -
Identifier Source: org_study_id